Insider Selling: Vaxcyte (NASDAQ:PCVX) COO Sells $111,420.00 in Stock

Vaxcyte, Inc. (NASDAQ:PCVX) COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $49.52, for a total value of $111,420.00. Following the transaction, the chief operating officer directly owned 158,494 shares in the company, valued at approximately $7,848,622.88. This trade represents a 1.40% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Jim Wassil also recently made the following trade(s):

• On Friday, May 1st, Jim Wassil sold 2,250 shares of Vaxcyte stock. The stock was sold at an average price of $56.83, for a total value of $127,867.50.
• On Tuesday, March 10th, Jim Wassil sold 7,395 shares of Vaxcyte stock. The stock was sold at an average price of $58.88, for a total value of $435,417.60.

Vaxcyte Trading Down 2.9%

NASDAQ:PCVX opened at $47.36 on Friday. The firm has a market cap of $6.84 billion, a P/E ratio of -6.88 and a beta of 1.24. The stock’s 50 day simple moving average is $55.20 and its 200-day simple moving average is $52.72. Vaxcyte, Inc. has a 12-month low of $29.08 and a 12-month high of $65.00.

Vaxcyte (NASDAQ:PCVX) last released its earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter last year, the business earned ($1.04) earnings per share. Research analysts forecast that Vaxcyte, Inc. will post -7.56 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of analysts recently weighed in on PCVX shares. Wall Street Zen downgraded Vaxcyte from a “sell” rating to a “strong sell” rating in a research note on Tuesday, April 28th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a report on Wednesday, April 8th. BTIG Research upped their target price on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research note on Wednesday, February 25th. Finally, Jefferies Financial Group reiterated a “buy” rating on shares of Vaxcyte in a research note on Tuesday, March 10th. Six research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the business. Seven Fleet Capital Management LP grew its stake in Vaxcyte by 406.4% in the first quarter. Seven Fleet Capital Management LP now owns 128,450 shares of the company’s stock worth $7,464,000 after purchasing an additional 103,085 shares in the last quarter. DV Trading LLC bought a new stake in shares of Vaxcyte in the 1st quarter worth approximately $1,162,000. Bank of America Corp DE lifted its holdings in shares of Vaxcyte by 73.4% in the 1st quarter. Bank of America Corp DE now owns 1,216,843 shares of the company’s stock worth $70,711,000 after purchasing an additional 515,209 shares during the last quarter. Stempoint Capital LP bought a new stake in shares of Vaxcyte in the 1st quarter worth approximately $3,432,000. Finally, Janus Henderson Group PLC raised its stake in Vaxcyte by 23.8% during the 1st quarter. Janus Henderson Group PLC now owns 16,575,875 shares of the company’s stock valued at $960,231,000 after acquiring an additional 3,188,687 shares in the last quarter. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Company Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.